Anika Therapeutics (ANIK) Long-Term Deferred Tax (2010 - 2026)

Anika Therapeutics (ANIK) has reported Long-Term Deferred Tax for 10 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 18.9% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $1.0 million, a 18.9% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 8.33% from the prior year.
• Long-Term Deferred Tax was $1.0 million for Q2 2026 at Anika Therapeutics, down from $1.2 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $1.5 million in Q1 2023 and troughed at $1.0 million in Q2 2026.
• A 5-year average of $1.3 million and a median of $1.3 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax decreased 20.95% in 2024 and advanced 8.33% in 2025, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $1.4 million in 2022, then gained by 2.76% to $1.5 million in 2023, then decreased by 20.95% to $1.2 million in 2024, then gained by 8.33% to $1.3 million in 2025, then decreased by 20.24% to $1.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $1.0 million (Q2 2026), $1.2 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.